Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for three approved abbreviated new animal drug applications (ANADAs) from Blue Ridge Pharmaceuticals, Inc., to Virbac AH, Inc.
This rule is effective May 2, 2002.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Lonnie W. Luther, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0209, e-mail: email@example.com.End Further Info End Preamble Start Supplemental Information
Blue Ridge Pharmaceuticals, Inc., 4249-105 Piedmont Pkwy., Greensboro, NC 27410, has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 200-270 for IVERHART (ivermectin) Tablets, NADA 200-281 for WORMEXX (pyrantel pamoate) Chewable Tablets, and NADA 200-302 for IVERHART Plus (ivermectin/pyrantel pamoate) Flavored Chewable Tablets to Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137. Accordingly, the agency is amending the regulations in 21 CFR 520.1193, 520.1196, and 520.2041 to reflect the transfer of ownership.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.Start List of Subjects
List of Subjects in 21 CFR Part 520End List of Subjects Start Amendment Part
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,End Amendment Part Start Part
PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGSEnd Part Start Amendment Part
1. The authority citation forEnd Amendment Part
2. Section 520.1193 Ivermectin tablets and chewables is amended in paragraph (b)(2) by removing “065274” and by adding in its place “051311”.
3. Section 520.1196 Ivermectin and pyrantel pamoate chewable tablet is amended in the section heading by removing “tablet” and by adding in its place “tablets”; and in paragraph (b) by removing “065274” and by adding in its place “051311”.
4. Section 520.2041 Pyrantel pamoate chewable tablets is amended in paragraph (b) by removing “065274” and by adding in its place “051311”.Start Signature
Dated: April 3, 2002..
Andrew J. Beaulieu,
Acting Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.
[FR Doc. 02-10793 Filed 5-1-02; 8:45 am]
BILLING CODE 4160-01-S